rheumatoid arthritisTo evaluate the persistence of biological drugs used as the first line of biological treatment in patients diagnosed with rheumatoid arthritis. The predictors associated with persistence have also been verified.We evaluated a historical cohort composed of users of the Brazilian National...
To the Editor: In an examination of the data that support the use of anti–tumor necrosis factor (TNF) drugs for rheumatoid arthritis, as reviewed by O'Dell (June 17 issue)1 and by Olsen and Stein (May 20 issue),2 one critical point is that there has been just a single randomized ...
Groups of 15 patients with active rheumatoid arthritis were treated for 24 weeks with zinc sulphate, trien, captopril, clozic in two doses or a combination of d-penicillamine and hydroxychloroquine. Serum histidine levels were monitored along with measures of disease activity including C-reactive pro...
Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(5):e2315872. doi:10.1001/jamanetworkopen.2023.15872 ArticlePubMedGoogle ScholarCrossref 13. Yang J, Yu S, Yang Z, et ...
We have examined the relationship between IgM-rheumatoid factor (RF) and responses to second-line drugs in patients with rheumatoid arthritis (RA). Patients with active RA who were beginning treatment with gold, methotrexate or both were studied. Clinical responses were assessed with ESR, joint cou...
The risk of cardiovascular disease is increased in patients with rheumatoid arthritis compared with the general population owing to the influence of traditional and non-traditional risk factors. Inflammation has a pivotal contribution and can accelerate
Most studies show antimalarials to be almost equivalent to chrysotherapy in potency. Antimalarials are indicated for active rheumatoid arthritis not optimally controlled with nonsteroidal anti-inflammatory drugs and for all cases of progressive disease. Therapy is continued indefinitely. Safe use of ...
10 Using ABI-RA (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients), a prospective ABIRISK study in RA, we aimed to analyze the association of antidrug antibodies (against TNF inhibitors,...
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treat... OBJECTIVES: To evaluate the risk of serious infections (SIs) in patients with RA treated with anti-TNF therapy with emphasis on the ...
Rheumatology: expensive, injectable arthritis drugs dominate in rheumatoid arthritis. They may lose some clout if cheaper, convenient orals get approved. Marc Iskowitz reports on pills in late testing and how much of an advantage analysts think they could have.(MMM THERAPEUTIC FOCUS)...